Revance will get sales people with neurology and movement disorders MD contacts. I didn't find it to be a big deal that they had long standing Botox rep relationships. We were still able to get meetings. On the most part, these MDs are about patient outcomes. Now that doesn't mean that the MD consultants for botox will change over or allow even allow a meeting. There are some that protect their outside income source. But, with the sunshine act in which all MDs income from industry is listed on line, the income has reduced significantly. Many companies have put caps on what each MD can earn from them.
Here is the webpage where you can see how much each MD makes from industry.
When I worked for a neurotoxin company the reps would utilize this sit to see how "hard" it was going to be to get a meeting with the MD. The more they made from Allergan as a consultant usually translated into how hard it was to meet with them.
The reason why botox has "fared very well" is that the most MDs utilized what they are most comfortable in dosing. They like known outcomes. Still, many will be compelled to meet with Revance reps as this is the first time that a new toxin has come onto the market with the value prop of longer duration. They will also love that it is not refrigerated.
Revance will find reps with strong relationships at the huge movement disorder hospitals like Stanford, UCSF, Cleveland clinic etc. They may even co-promote with another company that already has the relationships with no conflict of interest.
Market Data 
Markets 
AI
